QUEST DIAGNOSTICS INC (DGX) Stock
DGX has an Alpha Score of 56 out of 100 (moderate), computed on Oct 30, 2026 from 3 of 4 sub-scores. 13 members of Congress disclosed 26 trades in DGX since 2013: 12 purchases and 14 sales, most recently Alan Armstrong (purchase, Mar 30, 2026). 6 of the hedge funds AlphaScala tracks reported DGX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $57.18M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Nov 3, 2026. Its trailing P/E ratio is 24.7 and its net margin 9.2% (key statistics as of Oct 22, 2026).
What is DGX's Alpha Score?
How it works →Alpha Score of 56 reflects moderate overall profile with strong momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded QUEST DIAGNOSTICS INC (DGX)?
Most recent: Alan Armstrong (purchase, Mar 30, 2026); records start Dec 30, 2013.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-11-03 | sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-10-30 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-10-30 | sale | $1k – $15k |
| Julia Letlow R-LA · House | 2025-07-24 | sale | $1k – $15k |
| Julia Letlow R-LA · House | 2025-04-28 | purchase | $1k – $15k |
| Carol Miller R-WV · House | 2025-03-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded DGX, with filing lags →Which hedge funds own DGX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 270K | $57.18M | +35% |
| Citadel Ken Griffin | 133K | $28.23M | -62% |
| Point72 Steve Cohen | 23K | $4.96M | NEW |
| Millennium Management Israel Englander | 11K | $2.42M | -77% |
| D.E. Shaw David Shaw | 5K | $1.02M | -97% |
| Bridgewater Associates Ray Dalio | 4K | $796.1K | +8% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are QUEST DIAGNOSTICS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 26, 26 | Pfeiffer Gary M | Director | SELL | 1.2K | $292K |
| Sep 1, 26 | Davis J. E. | CEO and President | SELL | 10.0K | $2.4M |
| Aug 28, 26 | Prevoznik Michael E | SVP & General Counsel | SELL | 16.0K | $3.9M |
| Aug 28, 26 | Prevoznik Michael E | SVP & General Counsel | SELL | 6.2K | $1.5M |
| Aug 28, 26 | Prevoznik Michael E | SVP & General Counsel | SELL | 430 | $105K |
| Jul 28, 26 | Delaney Mark E | SVP & Chief Commercial Officer | SELL | 1.6K | $376K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are DGX's key statistics?
Key statistics as of Oct 22, 2026
How does DGX's valuation compare with the Healthcare sector?
| Metric | DGX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 24.7 | 27.0 | 102 |
| Net margin | 9.19% | 4.64% | 150 |
| Return on equity | 14.49% | 6.41% | 169 |
| Dividend yield (payers) | 2.10% | 1.69% | 52 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
DGX price chart
Powered by TradingViewWhat does QUEST DIAGNOSTICS INC do?
Quest Diagnostics Inc. is a leading independent provider of diagnostic testing, information, and services in the United States. The company generates the majority of its revenue from clinical testing, anatomic pathology, esoteric testing, and substance abuse testing, conducted through a national network of approximately 2,300 patient service centers, as well as doctors' offices and hospitals. It also operates a diagnostic solutions segment offering clinical trials testing, risk-assessment services, and information technology solutions to support healthcare providers. Quest Diagnostics empowers individuals, physicians, and organizations with diagnostic insights derived from one of the world's largest databases of de-identified clinical lab results, enabling disease identification, treatment, healthy behaviors, and improved healthcare management. The company serves one in three adult Americans and half of U.S. physicians and hospitals annually, while partnering through joint ventures like Sonora Quest Laboratories and Diagnostic Lab of Michigan for regional laboratory services and hospital lab management. Innovations include advanced tests such as Quest Flow Cytometry MRD for Myeloma and Haystack MRD for cancer monitoring. Founded in 1996 and headquartered in Secaucus, New Jersey, Quest Diagnostics plays a vital role in the diagnostics and research industry within the healthcare sector.